Why Recursion Pharmaceuticals Stock Is Tumbling Thursday
Why Recursion Pharmaceuticals Stock Is Tumbling Thursday
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are trading lower Thursday after the company announced a proposed offering of its common stock.
Recursion Pharmaceuticals Inc (納斯達克: RXRX)的股票週四交易較低，此前該公司宣佈擬議發行普通股。
What Happened: Recursion announced that it intends to offer and sell 30,769,230 shares of its common stock for $6.50 per share in an underwritten public offering.
發生了什麼事: Recursion宣佈，擬以6.5美元/股向公衆發行30,769,230股普通股。
The clinical-stage biotech company also said it plans to grant the underwriters a 30-day option to purchase up to an additional 4,615,384 of the shares being offered. All of the shares are being sold by Recursion.
這家臨床階段的生物技術公司還表示，計劃向承銷商提供30天購買額外的4,615,384股股票的選擇權。所有股票均由Recursion出售。
Recursion expects to receive total gross proceeds of approximately $200 million. The offering is expected to close on or about June 28. Recursion had $296.3 million in cash and cash equivalents as of March 31.
Recursion希望獲得約2億美元的總募集資金。發行預計將於6月28日左右結束。截至3月31日，Recursion擁有2.963億美元的現金及現金等價物。
Why It Matters: The proposed offering comes just days after Recursion held its annual investor day. NVIDIA Corp (NASDAQ:NVDA) CEO Jensen Huang made an appearance at the event to discuss the role AI will play in drug discovery and development in the future.
爲什麼它很重要: 這次擬議發行股票的消息發佈僅數天之後，Recursion舉行了年度投資者日活動。英偉達公司(NVDA納斯達克)首席執行官Jensen Huang在活動中露面，討論人工智能在未來藥物發現和研究中的作用。
Recursion and Nvidia announced a collaboration last year to accelerate development of AI foundation models for biology. Nvidia also reported investments in multiple companies, including Recursion, in a 13-F filing with the SEC in February. According to the filing, Recursion is Nvidia's second-largest investment after Arm Holdings.
Recursion和Nvidia去年宣佈了合作，加速基於生物學的人工智能基礎模型的開發。Nvidia在2月份提交給美國證券交易委員會的13F申報文件中，還報告了對多家公司的投資，其中包括Recursion。根據該申報文件，Recursion是英偉達股票後的第二大投資。
RXRX Price Action: Recursion Pharmaceuticals shares were down 20.1% at $7.00 at the time of writing, according to Benzinga Pro.
RXRX股票行情: 據Benzinga Pro消息，Recursion Pharmaceuticals股票在撰寫本文時下跌20.1%，報7.00美元。
Photo: Shutterstock.
照片：shutterstock。
譯文內容由第三人軟體翻譯。